<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:338587235;
mso-list-template-ids:528388624;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
-->@-ms-viewport {
width: device-width;
}
</style><!--[if gte mso 9]><xml>
</xml><![endif]--><!--[if gte mso 9]><xml>
</xml><![endif]-->
<!--[if gte mso 9]>
<xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
<o:PixelsPerInch>96</o:PixelsPerInch>
</o:OfficeDocumentSettings>
</xml>
<![endif]-->
<meta name="viewport" content="width=device-width, initial-scale=1">
</head>
<body lang="EN-ZA" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p><strong><span style="font-family:"Calibri",sans-serif"><o:p> </o:p></span></strong></p>
<p><strong><span style="font-family:"Calibri",sans-serif">Beyond the Medicines/Drugs Dichotomy: Historical Perspectives on Good and Evil in Pharmacy<o:p></o:p></span></strong></p>
<p><strong><span style="font-family:"Calibri",sans-serif">University of Johannesburg</span></strong><span style="font-family:"Calibri",sans-serif"><br>
<strong><span style="font-family:"Calibri",sans-serif">5-7 December 2019</span></strong><o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">The dichotomy between pharmacologically-active substances considered legitimate (and therefore worthy of regulation as medicines, and also provided as public goods) and those considered problematic (and therefore
deserving of moral and legal opprobrium, prohibition and sanction) has informed global regulatory regimes for decades. (Andy Gray, 2017)<o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">Drug policies and ways of thinking and talking about substances and treatment approaches are changing fast, both at national and international levels. These changes reflect a growing acknowledgement of core
contradictions within the legislative regimes Gray described above, crafted respectively for ‘drugs’ and ‘medicines’ from the nineteenth-century onwards. Subversions of this dichotomy have lately become more apparent in the public eye – for example, in widespread
addiction to opioid painkillers; in the repurposing of pharmaceuticals for pleasure, sedation or sociability; in the scientific legitimation of previously restricted drug alkaloids for medical application. Increasing criticism of ‘war-on-drugs’ style governance,
the liberalisation of cannabis laws, and the advocacy of harm reduction approaches to drug treatment are among the indications of shifting views even within governments themselves.<o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">The organizers of this event argue that precise historical understandings of how this dichotomy has worked in practice, in multiple and very different contexts, are necessary in order to map possible alternatives
and futures. To clearly identify who established and maintained classificatory boundaries, what interests lay behind their actions, how they have been challenged, and why it is only now that faith in them seems to be waning are important tasks for historians
of health, medicines and modernities, and those working in related fields and disciplines.<o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">This event at the University of Johannesburg aims to draw together those addressing the questions below in their research. We invite submissions from postgraduates, together with emerging and established scholars,
and are keen to include studies from around the world, as well as those that look at international or transnational contexts.<o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">Guiding questions:<o:p></o:p></span></p>
<ul type="disc">
<li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
What knowledge was generated to justify distinctions between medicines/drugs? By whom? How were decisions made about what evidence could be considered authoritative?<o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
Which groups and/or disciplines were involved in establishing or challenging the emergence of this dichotomy and what determined their success or failure?<o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
How have histories of various substances been created and deployed in justifying or disputing this dichotomy?<o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
What values have driven pharmaceutical technologies and their regulation? How have ideas about 'good' and 'evil' framed scientific and political discussions?<o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
How long has a shift towards a neuro-chemical society been happening and with what effects? Has it necessarily been a dehumanising process?<o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
Have chronologies of commodification, lawmaking and enforcement followed similar routes in different countries or contexts?<o:p></o:p></li><li class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;mso-list:l0 level1 lfo1">
How do historians recover neuro-chemical biographies, and what do these reveal about individual or collective experiences of the medicines/drugs dichotomy in practice?<o:p></o:p></li></ul>
<p><span style="font-family:"Calibri",sans-serif">The event is funded by the Wellcome Trust and is jointly organised by the
<a href="https://www.uj.ac.za/faculties/humanities/department-of-historical-studies">
Department of History at the University of Johannesburg </a>and The Centre for the Social History of Health and Healthcare (CSHHH) Glasgow through the 'Changing Minds: Psychoactive Substances in African and Asian History' project. <o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">The event will take place from 5 to 7 December 2019 at the University of Johannesburg.<o:p></o:p></span></p>
<p><strong><span style="font-family:"Calibri",sans-serif">Call for Papers</span></strong><span style="font-family:"Calibri",sans-serif"><br>
Please submit a title, an abstract of no more than 200 words which addresses some of the above questions, along with a narrative biography of 200 words, to Caroline Marley (<a href="mailto:caroline.marley@strath.ac.uk">caroline.marley@strath.ac.uk</a>) and
Thembisa Waetjen (<a href="mailto:twaetjen@uj.ac.za">twaetjen@uj.ac.za</a>) by <strong><span style="font-family:"Calibri",sans-serif">20 September 2019</span></strong>. <o:p></o:p></span></p>
<p><span style="font-family:"Calibri",sans-serif">Applicants will be informed of the committee’s decision by 4 October 2019.<o:p></o:p></span></p>
<p><strong><span style="font-family:"Calibri",sans-serif">Funding</span></strong><b><span style="font-family:"Calibri",sans-serif"><br>
</span></b><span style="font-family:"Calibri",sans-serif">This event is made possible by the generous support of the Wellcome Trust. Some funding for travel and accommodation is available, and will be prioritised for graduate students, post-doctoral fellows
and early career researchers, particularly where they are located at institutions in the Global South. <o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
<table width="100%" border="0" cellspacing="0" cellpadding="0" style="width:100%;">
<tbody>
<tr>
<td align="left" style="text-align:justify;"><font face="arial,sans-serif" size="1" color="#999999"><span style="font-size:11px;">This communication is intended for the addressee only. It is confidential. If you have received this communication in error, please
notify us immediately and destroy the original message. You may not copy or disseminate this communication without the permission of the University. Only authorised signatories are competent to enter into agreements on behalf of the University and recipients
are thus advised that the content of this message may not be legally binding on the University and may contain the personal views and opinions of the author, which are not necessarily the views and opinions of The University of the Witwatersrand, Johannesburg.
All agreements between the University and outsiders are subject to South African Law unless the University agrees in writing to the contrary.
</span></font></td>
</tr>
</tbody>
</table>
</body>
</html>